{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:16:00Z","timestamp":1775078160494,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clgc.2022.03.008","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T21:52:26Z","timestamp":1647553946000},"page":"388.e1-388.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I\/II Study by the Spanish Oncology Genitourinary Group"],"prefix":"10.1016","volume":"20","author":[{"given":"Xavier","family":"Garc\u00eda-del-Muro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Perez-Gracia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"\u00c1ngel Climent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan A.","family":"Virizuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aranzazu","family":"Gonz\u00e1lez del Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iciar","family":"Garc\u00eda Carbonero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"\u00c1lvarez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Garc\u00eda-Donas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Gil-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro-Gonz\u00e1lez","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.03.008_bib0001","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019. CA","author":"Siegel","year":"2019","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.clgc.2022.03.008_bib0002","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16341","article-title":"Urinary RKIP\/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma","author":"Papale","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2022.03.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2012.06.004","article-title":"Current and future systemic treatments for renal cell carcinoma","author":"Fisher","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2017.11.009","article-title":"Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma","author":"Climent","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.clgc.2022.03.008_bib0005","first-page":"1016","article-title":"VEGF inhibitors in renal cell carcinoma","volume":"14","author":"Vachhani","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0006","article-title":"SEER Cancer Statistics Review, 1975-2018","author":"Howlader","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2022.03.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2022.03.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.03.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-018-0061-6","article-title":"Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma","author":"Motzer","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2022.03.008_bib0011","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.617","article-title":"Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC)","author":"Motzer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.609","article-title":"Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab\u00a0+\u00a0ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","author":"Tannir","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2018.07.009","article-title":"Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS review","author":"Bracarda","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2022.03.008_bib0015","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clgc.2022.03.008_bib0016","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.03.008_bib0017","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-014-1295-4","article-title":"Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma","author":"You","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-020-01092-0","article-title":"Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma","author":"Lee","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2022.03.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(12)70241-3","article-title":"Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials","author":"Tran","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.03.008_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0022","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5009","article-title":"Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC)","author":"Motzer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-013-2333-4","article-title":"Circulating proteins as potential biomarkers of sunitinib and interferon-\u03b1 efficacy in treatment-na\u00efve patients with metastatic renal cell carcinoma","author":"Harmon","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-014-2539-0","article-title":"Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma","author":"Motzer","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2022.03.008_bib0026","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2022.03.008_bib0027","doi-asserted-by":"crossref","DOI":"10.4161\/cbt.27150","article-title":"First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile","author":"Iacovelli","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clgc.2022.03.008_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.29888","article-title":"Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma","author":"Beaumont","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.03.008_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175920","article-title":"Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom","author":"Amdahl","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2022.03.008_bib0030","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-399","article-title":"Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain","author":"Villa","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2022.03.008_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011673.pub2","article-title":"Immunotherapy for metastatic renal cell carcinoma","author":"Unverzagt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clgc.2022.03.008_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2016.08.012","article-title":"First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis","author":"Rousseau","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.clgc.2022.03.008_bib0033","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.11-4-397","article-title":"TNF-\u03b1 in cancer treatment: molecular insights, antitumor effects, and clinical utility","author":"van Horssen","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2022.03.008_bib0034","author":"Voss","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.03.008_bib0035","article-title":"Transforming growth factor-\u03b21 enhances proliferative and metastatic potential by up-regulating lymphoid enhancer-binding factor 1\/integrin \u03b1M\u03b22 in human renal cell carcinoma","author":"Liu","year":"2020","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.clgc.2022.03.008_bib0036","article-title":"High expression of chemokine CCL2 is associated with recurrence after surgery in clear-cell renal cell carcinoma","author":"Yang","year":"2016","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.clgc.2022.03.008_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010159","article-title":"Immune Cell-associated protein expression helps to predict survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and optional adjuvant chemotherapy","author":"Taubert","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.clgc.2022.03.008_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2015.03.019","article-title":"Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients","author":"Powles","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:17Z","timestamp":1761564917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1558767322000647"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.03.008","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I\/II Study by the Spanish Oncology Genitourinary Group","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}